DABIGARTAN: HOW TO SELECT AN OPTIMAL DOSE IN CLINICAL PRACTICE?
Abstract
Criteria of selection of an optimal dose of Dabigartan for preventing thromboembolism in patients with atrial fibrillation are considered.
References
1. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology. Guidelines for the management of atrial fibrillation. // Eur. Heart J.-2010.- Vol. 31.- P. 2369 - 2429.
2. Conway D.S.G., Heeringa J., Van Der Kuip D.A.M. et al. Atrial Fibrillation and the Prothrombotic State in the Elderly: The Rotterdam Study // Stroke.- 2003.- Vol. 34.- P. 413 - 417.
3. Feinberg W.M., Blackshear J.L., Laupacis A. et al. Prevalence, Age Distribution, and Gender of Patients With Atrial Fibrillation: Analysis and Implications // Arch. Intern. Med.- 1995.- Vol. 155.- P. 469 - 473.
4. Flegel K.M., Shipley M.J., Rose G. Risk of stroke in non-rheumatic atrial fibrillation // The Lancet.- 1987.- Vol. 329.- P. 526 - 529.
5. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation // Ann. Intern. Med.- 2007.- Vol. 146.- P. 857 - 867.
6. Olesen B., Lip G.Y.H., Lindhardsen J. et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study // Thromb. Haemost.- 2011.- Vol. 106.- P. 739 - 749.
7. The ACTIVE Investigators. Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation // N. Engl. J. Med.- 2009.- Vol. 360.- P. 2066 - 2078.
8. Hylek E.M., Skates S.J., Sheehan M.A. et al. An Analysis of the Lowest Effective Intensity of Prophylactic Anticoagulation for Patients with Nonrheumatic Atrial Fibrillation // N. Engl. J. Med.- 1996.- Vol. 335.- P. 540 - 546.
9. Birman-Deych E., Radford M.J., Nilasena D.S. et al. Use and Effectiveness of Warfarin in Medicare Beneficiaries With Atrial Fibrillation // Stroke.- 2006.- Vol. 37.- P. 1070 - 1074.
10. Гиляров М.Ю., Новикова Н.А., Саркисова Н.Д. и соавт. Оценка полноты соблюдения режима антитромботической терапии больными с фибрилляцией предсердий // Кардиология и сердечнососудистая хирургия.- 2011.- Т. 4.- С. 71 - 75.
11. Nieuwlaat R., Capucci A., Lip G.Y.H. et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation // Eur. Heart J.- 2006.- Vol. 27.- P. 3018 - 3026.
12. Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation // N. Engl. J. Med.- 2009.- Vol. 361.- P. 1139 - 1151.
13. Gulseth M.P., Wittkowsky A.K., Fanikos J. et al. Dabigatran Etexilate in Clinical Practice: Confronting Challenges to Improve Safety and Effectiveness // Pharmacotherapy.- 2011.- Vol. 31.- P. 1232 - 1249.
14. Roskell N.S., Lip G.Y.H., Noack H. et al. Treatments for stroke prevention in atrial fibrillation: A network meta-analysis and indirect comparisons versus dabigatran etexilate // Thromb. Haemost.- 2010.- Vol. 104.- P. 1106 - 1115.
15. Pisters R., Lane D.A., Nieuwlaat R. et al. A novel userfriendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey // Chest.- 2010.- Vol. 138.- P. 1093 - 1100.
16. Eikelboom J.W., Wallentin L., Connolly S.J. et al. Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation. Clinical Perspective // Circulation.- 2011.- Vol. 123.- P. 2363 - 2372.
Review
For citations:
Gilyarov M.Yu. DABIGARTAN: HOW TO SELECT AN OPTIMAL DOSE IN CLINICAL PRACTICE? Journal of Arrhythmology. 2012;69(69):77-80. (In Russ.)
Views:
136
Email this article 